ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: PP04

My Multidisciplinary Healthcare Team and Patient Advocacy Groups Saved My Life

Tedi LaMere1, Michael Linn2 and David Bammert3, 1Relapsing Polychondritis Foundation, Kalispell, MT, 2Relapsing Polychondritis Foundation, New York, NY, 3Relapsing Polychondritis Foundation, Houston, TX

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, cartilage, Cartilage Degradation, Inflammation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: Patient Perspectives Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: I enjoyed being physically active my entire life – climbing mountains, hunting, and hiking. This drastically changed around 2012, when I noticed that I was increasingly experiencing shortness of breath and fatigue, despite being physically fit. I developed a nagging cough and my heart function decreased dramatically. I was tested for numerous conditions, but a diagnosis eluded me, and my health continued to deteriorate.  Ironically, at the time, I was working as a respiratory therapist and was helping patients breathe, yet I could not breathe! I had to leave the career I was passionate about because my health became so poor. Eventually, my doctors ran out of potential diagnoses and began to discount my symptoms and brush me off. Meanwhile, my joints and tendons began to swell and become painful, my airways were collapsing, and I had to endure chemotherapeutic infusions to save my life.

Eventually, I was diagnosed with a rare autoimmune disease called relapsing polychondritis (“RP”), which is characterized by recurrent inflammation of cartilage in the body. RP is difficult to diagnose, challenging to treat and currently is not curable.

Intervention:

After trying to schedule an appointment at the National Institutes of Health (NIH) for quite some time, I had to postpone my visit because I became too sick to travel. Living in Montana, traveling to Bethesda, Maryland was overwhelming and simply not feasible – both physically and financially.

Thankfully, the RP Foundation and Race for RP established a fund to support the Friends of Patients at the NIH program (“Friends of Patients”) to offset travel costs and assist with providing for essential needs. The fund directly benefits RP patients and their families and advances RP research. Fortunately, I received assistance with transportation and made it to my appointments at the NIH! The clinicians and research scientists at the NIH identified several serious health conditions that could easily have cost me my life had they not been addressed, including cardiac amyloidosis, multiple pulmonary embolisms, and airways collapsing nearly 100%.

Maintenance:

Currently, my medications are addressing the severe inflammation and heart condition caused by RP. High-dose corticosteroids have undoubtedly saved my life but have also resulted in significant damage to my body as well. Chimeric monoclonal antibody infusions also seem to manage my symptoms, and anticoagulant therapy reduces the risk of abnormal blood clot formation.

Quality of Life:

I am grateful for the medical treatments that saved my life, yet I continue to have numerous daily struggles that I have learned to live with. I experience brain fog and joint pain all the time, and my heart and lung functions are greatly impaired. I have compression fractures in my back. I developed Cushing’s disease and diabetes and gained eighty pounds due to high-dose corticosteroids. However, my health is not declining at the rapid pace that it was prior to visiting NIH. Despite the severity of my symptoms, I remain hopeful that researcher scientists will unlock the mysteries of my disease and prolong my life – and the lives of others. I cannot thank NIH, Friends of Patients, RP Foundation, and Race for RP enough!

Tedi LaMere, a Registered Respiratory Therapist (RRT) with a Neonatal/Pediatric Specialist (NPS) certification, pictured outdoors prior to being diagnosed with relapsing polychondritis

Tedi LaMere, RRT-NPS and research advocate, pictured after being diagnosed with relapsing polychondritis

Tedi LaMere’s patient advocacy groups (Relapsing Polychondritis Foundation, Friends of Patients at NIH, and Race for RP) worked together to facilitate her healthcare.


Disclosure: T. LaMere, None; M. Linn, None; D. Bammert, None.

To cite this abstract in AMA style:

LaMere T, Linn M, Bammert D. My Multidisciplinary Healthcare Team and Patient Advocacy Groups Saved My Life [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/my-multidisciplinary-healthcare-team-and-patient-advocacy-groups-saved-my-life/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/my-multidisciplinary-healthcare-team-and-patient-advocacy-groups-saved-my-life/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology